Trial Profile
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs Lanadelumab (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Dyax; Shire
- 23 Feb 2017 Results published in a Shire media release.
- 23 Feb 2017 Primary endpoint (The number of attacks of angioedema per week) has been met.
- 23 Feb 2017 Results assessing safety and efficacy of Lanadelumab, published in the New England Journal of Medicine